Abstract
A 17-year-old female patient with pyridoxine non-responsive homocystinuria, treated with 20 g of betaine per day, developed a strong body odour, which was described as fish-like. Urinary trimethylamine (TMA) was measured and found to be markedly increased. DNA mutation analysis revealed homozygosity for a common allelic variant in the gene coding for the TMA oxidising enzyme FMO3. Without changing diet or betaine therapy, riboflavin was given at a dose of 200 mg per day. An immediate improvement in her odour was noticed by her friends and family and urinary TMA was noted to be greatly reduced, although still above the normal range.
Gradual further reductions in TMA (and odour) have followed whilst receiving riboflavin. Throughout this period, betaine compliance has been demonstrated by the measurement of dimethylglycine (DMG) excretion, which has been consistently increased. Marked excretions of DMG when the odour had subsided also demonstrate that DMG was not the source of the odour.
This patient study raises the possibility that betaine may be converted to TMA by intestinal flora to some degree, resulting in a significant fish odour when oxidation of TMA is compromised by FMO3 variants. The possibility exists that the body odour occasionally associated with betaine therapy for homocystinuria may not be related to increased circulating betaine or DMG, but due to a common FMO3 mutation resulting in TMAU. Benefits of riboflavin therapy for TMAU for such patients would allow the maintenance of betaine therapy without problematic body odour.
Competing interests: None declared.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdelmalek MF, Angulo P, Jorgensen RA et al (2001) Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 96:2711–2717
Burns SP, Holmes HC, Chalmers RA, Johnson A, Isles RA (1998) Proton NMR spectroscopic analysis of multiple acyl-CoA dehydrogenase deficiency – capacity of the choline oxidation pathway for methylation in vivo. Biochim Biophys Acta 1406:274–282
Busby MG, Fischer L, Da Costa KA et al (2004) Choline- and betaine- defined diets for use in clinical research and for the management of trimethylaminuria. J Am Diet Assoc 104:1836–1845
Chalmers RA, Bain MD, Iles RA (2003) Diagnosis of trimethylaminuria in children: marine fish versus choline load test. J Inherit Metab Dis 26 (Suppl 2):(448-P) 224
Fraser-Andrews EA, Manning NJ, Ashton GHS, Eldridge P, McGrath JA, Menagé H (2003) Fish odour syndrome with features of both primary and secondary trimethylaminuria. Clin Exp Dermatol 28:203–205
Heijthuijsen JHFG, Hansen TA (1989) Betaine fermentation and oxidation by marine Desulfuromonas strains. Appl Environ Microbiol 55(4):965–969
Humbert JR, Hammond KB, Hathaway WE, Marcoux JG, O’Brien D (1970) Trimethylaminuria: the fish-odour syndrome. Lancet 2:770–771
Kraus JP, Kozich V (2001) Cystathione beta-synthase and its deficiency. Homocysteine in Health and Disease. Carmel R, Jacobsen DW (eds) Cambridge University Press Chapt.20: 223–243
Lee WG, Yu JS, Turner BB, Murray KE (1976) Trimethylaminuria: fishy odors in children. N Engl J Med 295:937–938
Mitchell SC (1996) The fish odour syndrome. Perspect Biol Med 39(4):514–526
Moolenaar SH, Poggi-Bach J, Engelke UFH, Cortisiaensen JMB et al (1999) Defect in dimethylglycine dehydrogenase, a new inborn error of metabolism: NMR spectroscopic study’. Clin Chem 45(4):459–464
Moune S, Hirschler N, Caumette P, WiIlison J, Matheron R (1999) Haloanaerobacter salinarius a novel halophilic fermentative bacterium that reduces glycine-betaine to trimethylamine with hydrogen or serine as electron donors; emendation of the genus Haloanaerobacter. Int J Syst Bacteriol 49:103–112
Naumann E, Hippe H, Gottschalk G (1983) Betaine: new oxidant in the stickland reaction and methanogenesis from betaine and l-alanine by a Clostridium sporogenes-Methanosarcina barkeri co-culture. Appl Environ Microbiol 45(2):474–483
Norris ER, Benoit GJ (1945) Studies on trimethylamine oxide III. Trimethylamine oxide excretion by the rat. J Biol Chem 158:443–448
Olsen RKJ, Olpin SE, Andresen BS et al. (2007) ETFDH mutations as a major cause of riboflavin- responsive multiple acyl-CoA dehydrogenation deficiency. Brain 130:2045–2054
Orphan Europe (2007) Cystadane (betaine anhydrous). Adjunctive treatment for homocystinuria. CYSTAD 07-03-6645 (Brochure)
Påby P, Ekelund S, Bøgeskov-Jensen I (1989) A case of intermittent hypermethioninemia as the cause of disagreeable body odour (in Danish). Ugeskr Laeger 151(24):1551–1552
Singh RH, Kruger WD, Wang L, Pasquali M, Elsas LJ (2004) Cystathionine beta-synthase deficiency: effects of betaine supplementation after methionine restriction in B6-nonresponsive homocystinuria. Genet Med 6(2):90–95
Schwahn BC, Hafner D, Hohlfeld T, Balkenhol N, Laryea MD, Wendel U (2003) Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. Br J Clin Pharmacol 55: 6–13
Smolin LA, Benevenga NJ, Berlow S (1981) The use of betaine for the treatment of homocystinuria. J Pediatr 99:467–472
Treacy EP, Ackerman BR, Chow LML et al (1998) Mutations of the flavin- containing monooxygenase gene (FMO3) cause trimethylaminuria. A defect in detoxication. Hum Mol Genet 7:839–845
Treacy E, Johnson D, Pitt JJ, Danks DM (1995) Trimethylaminuria, fish odour syndrome: a new method of detection and response to treatment with metronidazole. J Inherit Metab Dis 18:306–312
Wilcken DEL, Wilcken B (1997) The long term outcome in homocystinuria. Rosenberg IH, Graham I, Ueland P et al. (eds): International Conference on Homocystineine Metabolism: From Basic Science to Clinical Medicine. Norwell, MA, Kluwer Academic: 51
Wunsche R (1940) Uber die Wirkung von Darmbakterien auf Trimethylammoniumbasen. Ber Ges Physiol Exp Pharm 118:303
Zschocke J, Kohlmueller D, Quak E, Meissner T, Hoffmann GF, Mayatepek E (1999) Mild trimethylaminuria caused by common variants in FMO3 gene. Lancet 354(9181):834–835
Zschocke J, Guldberg P, Wevers RA et al (2002) Molecular studies in flavin-containing mono-oxygenase 3 (FMO3) deficiency (abstract). J Inherit Metab Dis 25(Suppl 1):168
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Ertan Mayatepek
Synopsis
Synopsis
Betaine-related body odour may be due to trimethylaminuria and respond to riboflavin therapy without lowering betaine dosage.
Rights and permissions
Copyright information
© 2011 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Manning, N.J., Allen, E.K., Kirk, R.J., Sharrard, M.J., Smith, E.J. (2011). Riboflavin-Responsive Trimethylaminuria in a Patient with Homocystinuria on Betaine Therapy. In: JIMD Reports - Case and Research Reports, 2012/2. JIMD Reports, vol 5. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2011_99
Download citation
DOI: https://doi.org/10.1007/8904_2011_99
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-28095-5
Online ISBN: 978-3-642-28096-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)